Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Antares Pharma has hired Peter Richardson to take on the roles of executive vice president of R&D and chief medical officer. Richardson previously served as the chief medical officer at Adare Pharmaceuticals.
Antios Therapeutics has appointed Katie Laessig to senior vice president of global regulatory affairs. Laessig previously served as vice president of therapeutic strategy and strategic drug development at IQVIA. Antios has also named Karen Fusaro as senior vice president of clinical operations. Fusaro was most recently vice president of clinical and regulatory operations at Melinta Therapeutics.
Michael Stocum has been named president and CEO of Bantam Pharmaceutical. Stocum is the former CEO of Inivata Limited.
Charles Morris has been appointed chief medical officer of Celyad Oncology. Most recently, Morris served as chief medical officer of Radius Health.
Joseph Sarret has taken over as CEO of CohBar. Sarret was formerly the chief business officer at Corium International.
Cytovia Therapeutics has appointed Stanley Frankel to chief medical officer. Previously, Frankel served as senior vice president of cellular therapy development at Bristol Myers Squibb.
Joanne Donovan, former chief medical officer at Catabasis, has been named the chief medical officer of Edgewise Therapeutics.
Evgen has hired Glen Clack to take on the role of chief medical officer. Clack previously served as the chief medical officer of Modulus Oncology.
William Greene has been named CEO of Fountain Therapeutics. Greene is currently the CEO of Iconic Therapeutics and will retain this role while leading Fountain.
Graphite Bio has appointed Jane Grogan to chief scientific officer. Previously, Grogan served as chief scientific officer at ArsenalBio.
Gregory Berk has been named chief medical officer of GT Biopharma. Berk most recently served as chief medical officer at Celularity. GT Biopharma has also appointed Jeffrey Miller, the company’s consulting chief medical officer, to consulting chief scientific officer.
Brian Zhang has taken the helm of Himalaya Therapeutics as its newest CEO. Previously, Zhang established and led a bioinformatics group at Hoffmann-La Roche.
Tim Kelly has been promoted from chief technical operations officer to chief operating officer at Homology Medicines.
Daniel Maneval, former vice president of research and nonclinical development at Halozyme Therapeutics, has been named the new chief scientific officer at January Therapeutics.
Kinarus AG has appointed Thierry Fumeaux to chief medical officer. Fumeaux is a former member of the Swiss National COVID Taskforce.
Lonza has named Jennifer Cannon senior vice president and global head of the CDMO’s mammalian biologics business. Cannon most recently served as AbbVie’s vice president of operations of commercial development.
Nimbus Therapeutics has hired Avinash Phadke as vice president of chemistry, manufacturing and controls (CMC), Bhaskar Srivastava as vice president of early clinical development and Ajay Upadhyay as vice president of clinical operations. Phadke was most recently vice president and head of CMC at Achillion Pharmaceuticals, while Srivastava previously served as Janssen’s senior director of early development for translational science and medicine in immunology. Upadhyay recently served as president at the consulting firm October Global Solutions.
Graham Dempsey has been named chief scientific officer and head of research and development at Q-State Biosciences. Dempsey has been with Q-State since 2014, most recently serving as the organization’s vice president of research and development.
Replimune has hired Sushil Patel to take on the chief commercial officer role. Patel is a former Genentech executive who headed the head, lung and rare cancers unit.
William Sandborn, a professor of medicine at the University of California, San Diego, has been named the new chief medical officer of Shoreline Biosciences.